Recently, the Arterial Network held a second 2018 primary medical forum based on the “new structure†in Hangzhou. Zhejiang Deshang Yunxing Image Technology Co., Ltd. (hereinafter referred to as "Deshang Yunxing") announced the completion of the B round of financing, Fosun Pharmaceutical subsidiary Shanghai Fosun Pingyao Investment Management Co., Ltd. led the investment, Huagai Medical Fund and investment, Deshang Hu Hairong, general manager of Yunxing, said in an interview with the arterial network that the amount of this round of financing and the company's valuation could not be disclosed for the time being.
This round of financing will be used to promote the market-oriented promotion of existing products and technological innovation and research and development of research projects, and promote the development of the company's business in the field of medical artificial intelligence, especially the development and landing of AI+ ultrasound.
Zhejiang Deshang Yunxing Image Technology Co., Ltd. was established in 2013, dedicated to medical imaging artificial intelligence assisted diagnosis system, 3D visualization precision preoperative planning, intraoperative navigation, postoperative evaluation and other technologies. The company's self-developed product "ultrasound thyroid nodule intelligent auxiliary diagnosis system" is at the world's leading level.
Hu Hairong believes that the reason why Deshang Yunxing can be recognized by Fosun Pingyao and Huagai Medical is as follows:
First, the self-developed AI deep learning framework. Deshang Yunxing's technical research and development personnel are applied mathematics. They have developed a lightweight and flexible AI deep learning framework, which has high computational efficiency and low power consumption.
Since the deep learning framework is developed by itself, they can modify the model and adjust the parameters to make the model more suitable for product development when developing AI products of different diseases.
Second, the company has entered the field of AI+ ultrasound, and the market for ultrasound is large. According to IHS statistics, in 2014, the global medical ultrasound diagnostic equipment market has reached about 6.2 billion US dollars. It is estimated that in 2019, the scale will reach 7.4 billion US dollars, with an average annual compound growth rate of 3.6%.
In 2014, the market for ultrasonic diagnostic equipment in China reached 6.9 billion yuan. With the release of rigid demand, upgrading, and continued policy advancement, China's ultrasonic equipment market will grow rapidly. It is estimated that in 2019, the market size of medical ultrasonic diagnostic equipment in China will reach 9.1 billion yuan, with an average annual compound growth rate of 5.7%. Ultrasound-assisted diagnostic systems can alleviate the problems that are lacking in primary ultrasound doctors on a large scale.
Third, the intelligent thyroid nodule intelligent assisted diagnosis system can directly judge the benign and malignant and generate an image analysis report. Accuracy far exceeds the level of ordinary doctors, product performance is recognized by doctors, and data support.
Fourth, most of the company's teams have a background of medical work, understanding both clinical needs and IT algorithms, so Deshang Yunxing's product positioning is very clear, and the research and development functions are also in line with the doctor's clinical needs.
Fifth, Desheng Yunxing's investor, Jiajia, focuses on hospital solutions and oncology solutions. They have signed up with tens of thousands of primary hospitals. These resources can help Deshang Yunxing quickly land its own products.
Tend to choose industrial capital
Arterial Network learned that in 2015, Company A introduced strategic investors Zhuhai Hejia Medical Equipment Co., Ltd. Zhuhai Hejia is one of the leaders in the domestic medical resource platform. The business focuses on the three medical industries of medical equipment, medical services and medical informatization , and at the same time builds two major medical resource platforms for mobile medical and medical finance.
In June 2018, the company introduced Shanghai Fosun Pingyao Investment Management Co., Ltd. and Huagai Pharmaceutical Health Industry Venture Capital (Wenzhou) as a strategic investor in the B round.
The introduction of strategic investors aims to bring into play the experience and resources of strategic investors in the medical industry , promote the market-oriented promotion of Deshang Yunxing's existing products and the technological innovation and research and development of the research projects, and promote the company in the field of medical artificial intelligence. Business development.
Fosun Pingyao is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a listed company. Focus on investment and mergers in the fields of biomedicine, medical devices, and medical services.
Established by Huagai Capital, Huagai Medical Fund is an equity investment fund focusing on the medical and health industry. It focuses on biomedicine, medical devices, medical services and other fields, focusing on industry mergers and acquisitions in the medical and health fields and high-tech growth in the early and mid-term. Technology-based enterprise investment opportunities.
The cumulative management scale is several billion RMB, which is jointly funded by more than 30 well-known listed companies in the medical and health fields, a number of large financial and insurance institutions, parent funds and government guidance funds. The Huagai Medical Health Fund of Huagai Medical is jointly established by Huagai Medical and Zhejiang listed companies. It is the first venture capital guiding fund in Zhejiang Province that has received both national and provincial support. The fund focuses on investing in high-tech enterprises with rapid growth in the early, middle and early stages of medical and health care in Zhejiang Province. Investment includes biopharmaceuticals, medical devices and other fields.
Two mature product systems
Deshang Yunxing has two mature product systems, one is AI+ ultrasound system, and the other is 3D visualization, surgical planning, and surgical navigation system.
The most well-known product of Deshang Yunxing is the intelligent auxiliary diagnosis system for ultrasound thyroid nodules.
The system is divided into training and scoring. The training principle relies on deep learning techniques to train computers with more than 100,000 ultrasound image samples with labeled results.
Traditional machine learning is artificially defined, such as whether the edge of the nodule is regular, the echo situation, and the subjective judgment criteria of the doctor. But if you rely on deep learning, you don't need these artificial feature definitions.
The labeled samples are divided into two categories, one is benign and the other is malignant. The neural network separately analyzes the features of the benign and malignant nodules according to the labeling conditions, and this process is more detailed than the human eye.
After the training is completed, Deshang Yunxing packaged the algorithm and network parameters into a software, which is a scoring system. It can be deployed on the Internet or a stand-alone version. This part is run by a common computer. You can use it for assisted diagnosis.
For the diagnosis of thyroid nodules, the average accuracy of doctors in the top three hospitals is currently 60%-70%, and the primary hospitals will be even lower. The accuracy rate of Deshang Yunxing auxiliary diagnosis system can reach about 85%.
Hu Hairong told the Arterial Network reporter that the Jiangcun Street Community Health Service Center in Xihu District of Hangzhou City is the first pilot unit in the city to create an artificial intelligence-assisted medical treatment center. Since the medical center was put into use in December 2017, as of April 2018, the thyroid examination of the ultrasound artificial intelligence clinic has received about 1,500 residents, of which about 20 were positive. In the future, Desheng Yunxing will also develop and deploy more artificial intelligence-assisted diagnostic systems to assist grassroots doctors in assisting graded diagnosis and treatment.
Deputy Prime Minister Sun Chunlan conducted a field trip to Demetics Ultrasound Diagnostic Robot - Thyroid Nodule Intelligent Assisted Diagnosis System deployed at the First Affiliated Hospital of Zhejiang University School of Medicine. Two patients were randomly selected at the scene, and the robot automatically analyzed that their nodules were benign, consistent with the doctor's interpretation. Vice Premier Sun Chunlan gave full recognition.
In addition, Director Yang Aiping of the Center for Capacity Building and Continuing Medical Education of the National Health and Family Planning Commission, Ma Zhaoyi, director of the Big Data Office of the Capacity Building and Continuing Medical Education Center of the National Health Planning Commission, and other relevant leaders visited the Jiangcun Street Community Health Service Center to conduct field research and settle in the center. "Zhejiang Institute of Mathematical Medicine - Medical Imaging Artificial Intelligence Aided Medical Center" recognizes the role of Deshang Yunxing products in grading diagnosis and treatment.
In addition to artificial intelligence-assisted diagnostic products, Deshang Yunxing's 3D visualization precision preoperative planning, intraoperative navigation, postoperative evaluation and other technical products are relatively mature. Hu Hairong said that the products had participated in some international competitions in 2012, and they were among the best. After 6 years of research and development, the 3D reconstruction segmentation speed is 10 times faster. At present, these products have been tested in a number of top three hospitals, and the products are expected to be approved by the regulatory authorities in the second half of this year.
Difficulties in the need to overcome the development of medical AI products
The medical image artificial intelligence auxiliary diagnosis system uses the large amount of data marked by experts to learn, can inherit the experience of experts, and reach the level of the doctors above the top three hospitals in a short period of time, helping the grassroots doctors shorten the learning cycle, rapidly improve the diagnosis level, and help the country. Graded diagnosis and treatment.
Hu Hairong told the arterial network reporter that although medical imaging artificial intelligence has great advantages, it still needs to solve the following three problems in order to truly reach clinical application:
The government's strong support, such as data: artificial intelligence training requires large quantities of high-quality data, and the hospital is currently an island of data, in order to protect the privacy of patients, the data will not be easily taken out.
CFDA certification requires a reasonable approval rule for artificial intelligence products. At present, the State Food and Drug Administration has not yet approved the details, which is in the stage of research and discussion. Without the CFDA certificate, it is impossible for a company to form a sales, which is not good for the development of the company.
Market education requires strong publicity by the government, the media and enterprises. Because medical imaging artificial intelligence diagnosis is a new thing, most doctors do not understand the diagnostic principles of artificial intelligence. The cost of market education is high, which affects the speed of product promotion. And relying solely on enterprises to educate the market, the efficiency is the bottom. Therefore, it is necessary for the government and the media to cooperate with each other to promote the marketization of artificial intelligence diagnostic products.
Vinegar,White Rice Vinegar,White Vinegar,Millet Vinegar
Chinese Seasoning (Shandong) Trading Co.,Ltd , https://www.zt-trading.com